Clinical Trial to Evaluate the Effect of a Probiotic Mixture on Signs and Symptoms of Irritable Bowel Syndrome

IBS - Irritable Bowel Syndrome Clinical Trial

Official title:

Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of a Probiotic Mixture on Signs and Symptoms of Irritable Bowel Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05565612
• Other study ID #: SII.PROB
• Status: Completed
• Phase: N/A
• Start date: October 10, 2022
• Est. completion date: March 1, 2024

Study information

• Verified date: October 2023
• Source: Laboratorio Industrial de Herbodietetica Aplicada S.L
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The clinical trial has a randomized, double-blind and placebo-controlled design, in which the effect of a probiotic mix wants to be evaluated, with a treatment of 12 weeks, in the evolution of the symptoms of Irritable Bowel Syndrome.

The 12 weeks of the treatment are structured in four in-person visits: Visit 1 (initial; week 0), Visit 2 (halfway; week 4), Visit 3 (halfway; week 8) and Visit 4 (final; week 12).

Description:

Below, the four visits that compose the study and what to do in each one of them are described:

Visit 1 or initial (Week 0)

With the aim of recruiting patients, all patients diagnosed with irritable bowel who go to a consultation in the participant centres shall be informed of the study. If the patient shows interest, they shall be given detailed information about the study and the implications of their participation so that they can sign the informed consent if they wish so. Before signing, the patients shall have enough time to read and consider the detailed information and ask the investigator. The process of recruitment of patients shall continue until the sample size is reached.

Once the informed consent is signed, a doctor trained for the study shall make the initial interview in which the patient is tested to meet all the criterion for inclusion and none for exclusion (see clause 5.3.) and their clinical history.

The investigator shall proceed to assign to the patient the participant number on the study and, according to a previously elaborated randomization list, they shall be assigned the treatment that they shall receive during the study.

Once gotten to this point, the investigator shall value the severity and the symptoms of the Irritable Bowel Syndrome, by means of the IBS-SSS and IBS-QOL questionnaires (Annex I and II).

The patient shall be given the treatment with the assigned code, enough for the next programmed visit.

They shall be asked to turn in a stool sample and the nurse staff shall take a blood sample.

Visit 2 (Week 4) and visit 3 (Week 8)

In the halfway visits, in addition to value the symptoms of the disease with the scales detailed on the variable clause, the investigator shall register the adverse occurrences reported by the patient in a Case Report Form (CRF), as well as the concomitant treatments used.

Furthermore, the compliance rate of the treatment shall be calculated through the counting of the vials given back by the patient.

The patient shall be given new treatment, with the same code, enough until the next visit.

Visit 4 (Week 12)

In this visit the symptoms of the disease shall be valued with the two scales used in the study and the treatments that the patient has required during the 12 weeks following the end of the treatment under consideration.

Same as the first visit, they shall be asked to turn in a stool sample and they shall be taken a blood sample.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: March 1, 2024
• Est. primary completion date: December 26, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Aged between 18-65 years old.

• Informed consent signed by the patient.

• Patients with Irritable Bowel Syndrome diagnosed by Roma IV criteria

Exclusion Criteria:

• Patients who took antibiotics until two weeks prior to study.

• Patients who have taken other probiotics two months prior.

• Patients with other intestinal inflammatory diseases.

• Pregnant, breastfeeding or patients who do not compromise to use an efficient contraceptive method during the development of the study.

Related Conditions & MeSH terms

• IBS - Irritable Bowel Syndrome
• Irritable Bowel Syndrome
• Syndrome

Intervention

Dietary Supplement:
• Normodigest Classic
Symbiotic composed of 15 probiotic strains and fructooligosaccharides as prebiotic
• Placebo
Compound based on maltodextrin and other excipients

Locations

Country	Name	City	State
Spain	MiBioPath UCAM	Murcia

Sponsors (1)

Lead Sponsor	Collaborator
Laboratorio Industrial de Herbodietetica Aplicada S.L

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Adverse events on weeks 4, 8 and 12	Number of adverse events reported by the patient at each visit	12 week
Primary	Change from baseline on IBS-SSS (Irritable Bowel Syndrome-Severity Scoring System) scale at 4, 8 and 12 weeks	IBS index measures the severity of the disease, wich takes into account aspects such as pain, abdominal distension, intestinal habit and quality of life of the patient with IBS; Categories of severity according to punctuation on the index IBS-SSS; Mild: 75 <175; Moderate: 175 <300; Severe: > 300	12 weeks
Secondary	Change from baseline on IBS-QoL (Irritable Bowel Syndrome-Quality of Life) index at 4, 8 and 12 weeks	IBS-QoL measures the impact of the disease on the quality of life of patients with IBS; The questionnaire consists of 34 questions with a score of 1 to 5 in each of them.	12 weeks
Secondary	Change from baseline on values of hemogram to final visit	Complete blood count	12 weeks
Secondary	Change from baseline on values of blood glucose to final visit	Blood glucose parameters (mg/dL)	12 weeks
Secondary	Change from baseline on values of blood sodium to final visit	Blood sodium parameters (mEq/L)	12 weeks
Secondary	Change from baseline on values of blood potassium to final visit	Blood potassium parameters (mEq/L)	12 weeks
Secondary	Change from baseline on values of blood chlorine to final visit	Blood chlorine parameters (mEq/L)	12 weeks
Secondary	Change from baseline on values of blood creatinine to final visit	Blood creatinine parameters (mg/dL)	12 weeks
Secondary	Change from baseline on values of blood HDL, LDL and total cholesterol to final visit	Blood HDL, LDL an total cholesterol parameters (mg/dL)	12 weeks
Secondary	Change from baseline on values of blood triglycerides to final visit	Blood triglycerides parameters (mg/dL)	12 weeks
Secondary	Change from baseline on values of blood C-reactive protein to final visit	Blood C-reactive protein parameters (mg/L)	12 weeks
Secondary	Change from baseline on values of blood gamma glutamyl transferase (GGT) to final visit	Blood GGT parameters (mg/L)	12 weeks
Secondary	Change from baseline on values of blood glutamic pyruvic transaminase (GPT) to final visit	Blood GPT parameters (mg/L)	12 weeks
Secondary	Gut microbiota changes from baseline to final visit	Alpha Diversity, Beta Diversity, and Composition, Using R16s Gene Sequencing of a Stool Sample	12 weeks
Secondary	Compliance rate at 4, 8 and 12 12 weeks	Assess compliance rate at each visit	12 weeks